This is a routine, immaterial insider sale by a director. No trading action warranted. Monitor for any larger insider sales or changes in filing patterns ahead of upcoming earnings or catalysts.
ARQT drugs
ARQT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $20.69entry
- T+1 · 6mo ago 0.00%α −0.54% · $20.69
- T+5 · 6mo ago −3.19%α −3.27% · $20.03
- T+20 · 5mo ago +12.28%α +14.00% · $23.23
- T+60 · 3mo ago +27.74%α +23.36% · $26.43
Price Chart
How similar events traded
Executive Summary
Director Patrick Burnett filed a Form 144 notice of intent to sell 222 shares of Arcutis Biotherapeutics (ARQT) worth approximately $4,673, representing a de minimis portion of his holdings. The shares were acquired via restricted stock vesting on May 1, 2026. This is a routine, small-dollar insider sale with no material signal.
Key Facts
- Insider: Director Patrick Burnett
- Shares to sell: 222 shares of common stock
- Approximate value: $4,673
- Acquisition: Restricted stock vesting on May 1, 2026
- Broker: Merrill Lynch
- Filing date: May 11, 2026
Financial Impact
Sale value of ~$4,673 is negligible relative to ARQT's $2.6B market cap (0.00018%)
Risk Factors
- No material risk, sale is de minimis and likely part of routine tax or estate planning
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-033615 |
| Document: 0001628280-26-033615-index.html | 0001628280-26-033615 |
| Document: 0001628280-26-033615.txt | 0001628280-26-033615 |
Track record
34 reports on ARQT
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers